NewPace develops a flexible and subcutaneous implantable cardioverter defibrillator (ICD) with no leads within the heart with a wireless rechargeable battery and Bluetooth communication. The NewPace defibrillator differs from standard ICDs in that it does not have leads in the heart. The rechargeable device is implanted subcutaneously with no need for fluoroscopy and communicates via Bluetooth with a smartphone. The string-shaped defibrillator requires one hour per year for wireless recharge and communicates at low energy with smartphones for monitoring. The subcutaneous implantation requires no in-patient care. NewPace partners with China-based Haisco Pharmaceutical.